The utilization of an anti-ADAM17 antibody or small molecule inhibitor can be considered for inhibition of CD16 shedding in case of combined cancer immunotherapy with antibodies, needing NK cells capable of mediating ADCC. Here, FCGR3A is linked to cancer.